IBX.AU · Imagion Biosystems Limited

-

Please sign in to comment on IBX.AU

1 Comment

Admin

3 years, 7 months ago

Imagion Biosystems Limited is currently in a long term downtrend where the price is trading 32.0% below its 200 day moving average.

From a valuation standpoint, the stock is 111.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 544.7.

Imagion Biosystems Limited's total revenue rose by 191.1% to $384K since the same quarter in the previous year.

Its net income has dropped by 48.2% to $-4M since the same quarter in the previous year.

Finally, its free cash flow fell by 204.6% to $-2M since the same quarter in the previous year.

Based on the above factors, Imagion Biosystems Limited gets an overall score of 1/5.

ISIN	AU000000IBX6
Industry	Diagnostics & Research
Sector	Healthcare
CurrencyCode	AUD
Exchange	AU

Market Cap	18M
Beta	2.53
Dividend Yield	0.0%
Target Price	None
PE Ratio	0.0

ABOUT

Imagion Biosystems Limited

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the MagSense nanoparticles for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.

IBX.AU · Imagion Biosystems Limited

-

Imagion Biosystems Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Imagion Biosystems Limited using a moving average strategy